SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Beauty Health Co. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Tuesday, 3/12/24, at 5:17pm ET   ·   For:  12/31/23   ·   Accession #:  1628280-24-10638   ·   File #:  1-39565

Previous ‘10-K’:  ‘10-K’ on 3/1/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   15 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/12/24  Beauty Health Co.                 10-K       12/31/23  110:13M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.40M 
 2: EX-21.1     Subsidiaries List                                   HTML     33K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     29K 
 8: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     42K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     31K 
14: R1          Cover                                               HTML     98K 
15: R2          Audit Information                                   HTML     35K 
16: R3          Consolidated Balance Sheets                         HTML    142K 
17: R4          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
18: R5          Consolidated Statements of Comprehensive Income     HTML    128K 
                (Loss)                                                           
19: R6          Consolidated Statements of Stockholders? Equity     HTML    126K 
                (Deficit)                                                        
20: R7          Consolidated Statements of Cash Flows               HTML    169K 
21: R8          Description of Business                             HTML     38K 
22: R9          Summary of Significant Accounting Policies          HTML     94K 
23: R10         Business Combinations                               HTML     89K 
24: R11         Revenue                                             HTML     60K 
25: R12         Balance Sheet Components                            HTML     62K 
26: R13         Leases                                              HTML     57K 
27: R14         Property and Equipment, net                         HTML     47K 
28: R15         Goodwill and Intangible Assets, net                 HTML     82K 
29: R16         Long-term Debt                                      HTML     64K 
30: R17         Fair Value Measurements                             HTML     64K 
31: R18         Income Taxes                                        HTML    147K 
32: R19         Employee Benefit Plan                               HTML     33K 
33: R20         Equity-Based Compensation                           HTML     85K 
34: R21         Commitments and Contingencies                       HTML     47K 
35: R22         Related-Party Transactions                          HTML     45K 
36: R23         Stockholders? Equity                                HTML     42K 
37: R24         Net Income (Loss) Attributable to Common            HTML     64K 
                Stockholders                                                     
38: R25         Restructuring Charges                               HTML     41K 
39: R26         Revision for Immaterial Misstatements               HTML    116K 
40: R27         Summary of Significant Accounting Policies          HTML    166K 
                (Policies)                                                       
41: R28         Business Combinations (Tables)                      HTML     82K 
42: R29         Revenue (Tables)                                    HTML     60K 
43: R30         Balance Sheet Components (Tables)                   HTML     68K 
44: R31         Leases (Tables)                                     HTML     61K 
45: R32         Property and Equipment, net (Tables)                HTML     46K 
46: R33         Goodwill and Intangible Assets, net (Tables)        HTML     84K 
47: R34         Long-term Debt (Tables)                             HTML     40K 
48: R35         Fair Value Measurements (Tables)                    HTML     56K 
49: R36         Income Taxes (Tables)                               HTML    149K 
50: R37         Equity-Based Compensation (Tables)                  HTML     82K 
51: R38         Net Income (Loss) Attributable to Common            HTML     65K 
                Stockholders (Tables)                                            
52: R39         Restructuring Charges (Tables)                      HTML     35K 
53: R40         Revision for Immaterial Misstatements (Tables)      HTML    115K 
54: R41         Description of Business (Details)                   HTML     43K 
55: R42         Summary of Significant Accounting Policies          HTML    102K 
                (Details)                                                        
56: R43         Business Combinations - Narrative (Details)         HTML     94K 
57: R44         Business Combinations - Schedule of reverse         HTML     40K 
                recapitalization consideration (Details)                         
58: R45         Business Combinations - Schedule of reverse         HTML     58K 
                recapitalization shares issued (Details)                         
59: R46         Business Combinations - Summary of assets acquired  HTML    129K 
                at fair value (Details)                                          
60: R47         Revenue - Narrative (Details)                       HTML     41K 
61: R48         Revenue - Revenue Disaggregated (Details)           HTML     41K 
62: R49         Revenue - Geographic Region (Details)               HTML     43K 
63: R50         Revenue - Allowance for Credit Loss (Details)       HTML     37K 
64: R51         Balance Sheet Components - Schedule of inventory    HTML     40K 
                (Details)                                                        
65: R52         Balance Sheet Components - Schedule of accrued      HTML     39K 
                payroll-related expenses (Details)                               
66: R53         Balance Sheet Components - Schedule of accrued      HTML     42K 
                expenses (Details)                                               
67: R54         Balance Sheet Components - Schedule of Long Lived   HTML     40K 
                Assets, by Geographic Region (Details)                           
68: R55         Balance Sheet Components - Narrative (Details)      HTML     31K 
69: R56         Leases - Schedule of Operating Right-of-use Assets  HTML     37K 
                and Lease Liabilities (Details)                                  
70: R57         Leases - Narrative (Details)                        HTML     32K 
71: R58         Leases - Schedule of Lease Liability Maturity       HTML     49K 
                (Details)                                                        
72: R59         Leases - Schedule of Supplemental Operating Lease   HTML     39K 
                Information (Details)                                            
73: R60         Property and Equipment, net (Details)               HTML     66K 
74: R61         Goodwill and Intangible Assets, net - Goodwill      HTML     38K 
                (Details)                                                        
75: R62         Goodwill and Intangible Assets, net - Intangible    HTML     69K 
                Assets (Details)                                                 
76: R63         Goodwill and Intangible Assets, net - Narrative     HTML     72K 
                (Details)                                                        
77: R64         Goodwill and Intangible Assets, net - Future        HTML     45K 
                Amortization Expense (Details)                                   
78: R65         Long-term Debt - Narrative (Details)                HTML    142K 
79: R66         Long-term Debt - Schedule of Long-term Debt         HTML     49K 
                (Details)                                                        
80: R67         Fair Value Measurements - Schedule of assets and    HTML     54K 
                liabilities measured at fair value on recurring                  
                basis (Details)                                                  
81: R68         Fair Value Measurements - Narrative (Details)       HTML     72K 
82: R69         Income Taxes - Schedule of income before income     HTML     39K 
                tax, domestic and foreign (Details)                              
83: R70         Income Taxes - Schedule of components of income     HTML     58K 
                tax expense (Benefit) (Details)                                  
84: R71         Income Taxes - Schedule of effective income tax     HTML     93K 
                rate reconciliation (Details)                                    
85: R72         Income Taxes - Schedule of deferred tax assets and  HTML     74K 
                liabilities (Details)                                            
86: R73         Income Taxes - Narrative (Details)                  HTML     50K 
87: R74         Income Taxes - Summary of Income Tax Contingencies  HTML     39K 
                (Details)                                                        
88: R75         Employee Benefit Plan (Details)                     HTML     33K 
89: R76         Equity-Based Compensation - Narrative (Details)     HTML    106K 
90: R77         Equity-Based Compensation - Schedule of stock       HTML     84K 
                option activity (Details)                                        
91: R78         Equity-Based Compensation - Schedule of valuation   HTML     56K 
                assumptions (Details)                                            
92: R79         Equity Based Compensation - Schedule of unvested    HTML     60K 
                share activity (Details)                                         
93: R80         Equity Based Compensation - Schedule of share       HTML     32K 
                based compensation (Details)                                     
94: R81         Equity Based Compensation - Schedule of stock       HTML     42K 
                based compensation expense (Details)                             
95: R82         Commitments and Contingencies (Details)             HTML     51K 
96: R83         Related-Party Transactions (Details)                HTML     87K 
97: R84         Stockholders? Equity (Details)                      HTML    101K 
98: R85         Net Income (Loss) Attributable to Common            HTML     64K 
                Stockholders - Schedule of basic and diluted                     
                earnings per share (Details)                                     
99: R86         Net Income (Loss) Attributable to Common            HTML     42K 
                Stockholders - Schedule of antidilutive securities               
                excluded from earnings per share computation                     
                (Details)                                                        
100: R87         Restructuring Charges (Details)                     HTML     45K  
101: R88         Restructuring Charges - Summary of Syndeo Program   HTML     41K  
                charges and Usage (Details)                                      
102: R89         Revision for Immaterial Misstatements - Narrative   HTML     47K  
                (Details)                                                        
103: R90         Revision for Immaterial Misstatements -             HTML    100K  
                Consolidated Statement of Comprehensive Income                   
                (Loss) (Details)                                                 
104: R91         Revision for Immaterial Misstatements -             HTML     63K  
                Consolidated Statement of Cash Flows (Details)                   
105: R92         Revision for Immaterial Misstatements -             HTML    101K  
                Consolidated Balance Sheet (Details)                             
107: XML         IDEA XML File -- Filing Summary                      XML    199K  
110: XML         XBRL Instance -- skin-20231231_htm                   XML   2.59M  
106: EXCEL       IDEA Workbook of Financial Report Info              XLSX    240K  
10: EX-101.CAL  XBRL Calculations -- skin-20231231_cal               XML    305K 
11: EX-101.DEF  XBRL Definitions -- skin-20231231_def                XML    909K 
12: EX-101.LAB  XBRL Labels -- skin-20231231_lab                     XML   2.28M 
13: EX-101.PRE  XBRL Presentations -- skin-20231231_pre              XML   1.53M 
 9: EX-101.SCH  XBRL Schema -- skin-20231231                         XSD    248K 
108: JSON        XBRL Instance as JSON Data -- MetaLinks              655±  1.00M  
109: ZIP         XBRL Zipped Folder -- 0001628280-24-010638-xbrl      Zip    778K  


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
  exhibit971-amendedclawba  
1 US-DOCS\143410591.3 THE BEAUTY HEALTH COMPANY AMENDED AND RESTATED CLAWBACK POLICY The Beauty Health Company (the “Company”) has adopted this Amended and Restated Clawback Policy (this “Policy”), effective as of October 2, 2023 (the “Effective Date”). This Policy amends, restates and supersedes in its entirety the Company’s Clawback Policy, which was originally adopted by the Company on May 4, 2021. Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy shall apply to current and former Officers. Each Officer shall be required to sign an acknowledgment pursuant to which such Officer will agree to be bound by the terms of, and comply with, this Policy; however, any Officer’s failure to sign any such acknowledgement shall not negate the application of this Policy to the Officer. 2. Compensation Subject to Policy This Policy shall apply to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is “received” shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is “received” in the Company’s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period. 3. Recovery of Compensation In the event that the Company is required to prepare a Restatement, the Company shall recover, reasonably promptly, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee has determined that recovery would be Impracticable. Recovery shall be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by the Company. For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any person’s right to voluntarily terminate employment for “good reason,” or due to a “constructive termination” (or any similar term of like effect) under any plan, program or policy of or agreement with the Company or any of its affiliates. 4. Manner of Recovery; Limitation on Duplicative Recovery The Committee shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation or


 
2 US-DOCS\143410591.3 Erroneously Awarded Compensation, reimbursement or repayment by any person subject to this Policy of the Erroneously Awarded Compensation, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by the Company or an affiliate of the Company to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already recovered by the Company from the recipient of such Erroneously Awarded Compensation may be credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person. 5. Administration This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose. The Board of Directors of the Company (the “Board”) may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and in such event references herein to the “Committee” shall be deemed to be references to the Board. Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company and its affiliates, equityholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the Company, as permitted under applicable law, including any Applicable Rules. 6. Interpretation This Policy will be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith. 7. No Indemnification; No Liability The Company shall not indemnify or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall the Company directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person’s potential obligations under this Policy. None of the Company, an affiliate of the Company or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy. 8. Application; Enforceability Except as otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any other clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates, including any such policies or


 
3 US-DOCS\143410591.3 provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based plan or award agreement thereunder or similar plan, program or agreement of the Company or an affiliate or required under applicable law (the “Other Recovery Arrangements”). The remedy specified in this Policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to the Company or an affiliate of the Company. 9. Severability The provisions in this Policy are intended to be applied to the fullest extent of the law; provided, however, to the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. 10. Amendment and Termination The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate automatically when the Company does not have a class of securities listed on a national securities exchange or association. 11. Definitions “Applicable Rules” means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association on which the Company’s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on which the Company’s securities are listed. “Committee” means the committee of the Board responsible for executive compensation decisions comprised solely of independent directors (as determined under the Applicable Rules), or in the absence of such a committee, a majority of the independent directors serving on the Board. “Erroneously Awarded Compensation” means the amount of Incentive-Based Compensation received by a current or former Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as determined on a pre-tax basis in accordance with the Applicable Rules. For Incentive-Based Compensation based on total stockholder return or stock price, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the Restatement, Erroneously Awarded Compensation is the Committee’s reasonable estimate of the effect of the Restatement on the total stockholder return or stock price upon which the Incentive-Based Compensation was received, with documentation of the determination of such reasonable estimate provided by the Company to the applicable listing exchange or association.


 
4 US-DOCS\143410591.3 “Exchange Act” means the Securities Exchange Act of 1934, as amended. “Financial Reporting Measure” means any measure determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non- GAAP/IFRS financial measures, as well as stock or share price and total equityholder return. “GAAP” means United States generally accepted accounting principles. “IFRS” means international financial reporting standards as adopted by the International Accounting Standards Board. “Impracticable” means that (a) the direct costs paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation; provided that the Company has (i) made reasonable attempts to recover the Erroneously Awarded Compensation, (ii) documented such attempt(s), and (iii) provided such documentation to the relevant listing exchange or association, (b) to the extent permitted by the Applicable Rules, the recovery would violate the Company’s home country laws pursuant to an opinion of home country counsel; provided that the Company has (i) obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in such violation, and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder. “Incentive-Based Compensation” means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after beginning service as an Officer; (b) who served as an Officer at any time during the performance period for that compensation; (c) while the Company has a class of securities listed on a national securities exchange or association; and (d) during the applicable Three-Year Period. “Officer” means each person who serves as an executive officer of the Company, as defined in Rule 10D-1(d) under the Exchange Act. “Restatement” means an accounting restatement to correct the Company’s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. “Three-Year Period” means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs the Company


 
5 US-DOCS\143410591.3 to prepare such Restatement. The “Three-Year Period” also includes any transition period (that results from a change in the Company’s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence. However, a transition period between the last day of the Company’s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.


 
1 US-DOCS\143410591.3 ACKNOWLEDGMENT AND CONSENT TO AMENDED AND RESTATED CLAWBACK POLICY The undersigned has received a copy of the Amended and Restated Clawback Policy (the “Policy”) adopted by The Beauty Health Company (the “Company”). For good and valuable consideration, the receipt of which is acknowledged, the undersigned agrees to the terms of the Policy and agrees that compensation received by the undersigned may be subject to reduction, cancellation, forfeiture and/or recoupment to the extent necessary to comply with the Policy, notwithstanding any other agreement to the contrary. The undersigned further acknowledges and agrees that the undersigned is not entitled to indemnification in connection with any enforcement of the Policy and expressly waives any rights to such indemnification under the Company’s organizational documents or otherwise. ___________________ Date ________________________________________ Signature ________________________________________ Name ________________________________________ Title


 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/12/248-K
For Period end:12/31/23NT 10-K
10/2/23
5/4/213,  8-K
 List all Filings 


15 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/14/23  Beauty Health Co.                 8-K/A:5,9  11/10/23   12:447K                                   Workiva Inc Wde… FA01/FA
12/01/23  Beauty Health Co.                 8-K:5,9    11/29/23   12:252K                                   Workiva Inc Wde… FA01/FA
11/13/23  Beauty Health Co.                 8-K:5,7,9  11/10/23   13:8.1M                                   Workiva Inc Wde… FA01/FA
 8/09/23  Beauty Health Co.                 8-K:5,7,9   8/03/23   14:482K                                   Workiva Inc Wde… FA01/FA
 4/19/23  Beauty Health Co.                 8-K:5,7,9   4/19/23   13:226K
 4/14/23  Beauty Health Co.                 8-K:5,9     4/12/23   12:223K
 2/28/23  Beauty Health Co.                 8-K:1,3,7   2/27/23   13:707K
11/15/22  Beauty Health Co.                 8-K:1,2,9  11/14/22   11:1.7M
 9/27/22  Beauty Health Co.                 8-K:1,7,8,9 9/26/22   12:494K
 3/01/22  Beauty Health Co.                 10-K       12/31/21  104:13M
 9/14/21  Beauty Health Co.                 8-K:1,2,3   9/09/21   13:1.6M
 5/10/21  Beauty Health Co.                 8-K:1,2,3,4 5/04/21   15:1.4M                                   Donnelley … Solutions/FA
 4/30/21  Beauty Health Co.                 8-K:5,9     4/29/21    3:242K                                   Donnelley … Solutions/FA
12/09/20  Beauty Health Co.                 8-K:1,3,7,912/08/20    7:16M                                    EdgarAgents LLC/FA
10/05/20  Beauty Health Co.                 8-K:1,3,5,8 9/29/20   12:865K                                   EdgarAgents LLC/FA
Top
Filing Submission 0001628280-24-010638   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 12:05:44.2pm ET